Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAGUAR HEALTH, INC.

(JAGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jaguar Health : Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021

09/27/2021 | 10:55am EST

Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy
Virtual event 1:00 PM to 2:10 PM Eastern
Registration open now for financial and business community; Click hereto register

SAN FRANCISCO, CA / ACCESSWIRE / September 27, 2021 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting an R&D Showcase webinar about cancer therapy-related diarrhea (CTD) on September 29, 2021 from 1:00 p.m. to 2:10 p.m. Eastern. The virtual event, open to the financial and business community, will address the importance of supportive care for cancer patients to address the debilitating diarrhea that can be experienced because of cancer therapy.

Jaguar founder and CEO Lisa Conte and Pravin Chaturvedi, PhD, Jaguar's acting Chief Scientific Officer and Chair of Scientific Advisory Board, will participate in the virtual event, which will also include commentary from three distinguished oncologists: Lee Schwartzberg, MD, FACP, who is affiliated with the Renown Institute for Cancer; Eric Roeland, MD, FAAHPM, Assistant Professor, Oregon Health & Science University; and Andrew Davies, MB BS, MSc, MD, FRCP, President of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Director of the Development in Palliative Medicine, St. Luke's Cancer Centre/Royal Surrey County Hospital.

Participation Instructions for R&D Showcase

Event is exclusively for investors, financial analysts, business media, and business development executives.

When: Wednesday, September 29, 2021 from 1:00 p.m. to 2:10 p.m. Eastern Time

Registration Link: Click Here

About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Napo EU S.p.A., the wholly owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros from Jaguar.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements related to the expectation that Ladenburg Thalmann will host a CTD-focused R&D Showcase webinar on September 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



accesswire.com
https://www.accesswire.com/665461/Jaguar-Health-Announces-that-Ladenburg-Thalmann-is-Hosting-RD-Showcase-Webinar-About-Cancer-Therapy-related-Diarrhea-on-September-29-2021

Disclaimer

Jaguar Health Inc. published this content on 27 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 September 2021 12:41:05 UTC.


ę Publicnow 2021
All news about JAGUAR HEALTH, INC.
11/23JAGUAR HEALTH, INC. : Changes in Registrant's Certifying Accountant, Financial Statements ..
AQ
11/23Jaguar Health Files $75 Million Mixed Shelf
MT
11/19JAGUAR HEALTH : Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofe..
PU
11/18JAGUAR HEALTH : Reports 2021 Third Quarter Financial Results - Form 8-K
PU
11/18Jaguar Health, Inc. Reports Consolidated Operating Results for the Third Quarter Ended ..
CI
11/17JAGUAR HEALTH : Reports 2021 Third Quarter Financial Results
PU
11/17JAGUAR HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/17Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/16Napo EU Appoints Massimo Mineo as General Manager
CI
11/16JAGUAR HEALTH : Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
PU
More news
Analyst Recommendations on JAGUAR HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 10,7 M - -
Net income 2021 -42,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,67x
Yield 2021 -
Capitalization 55,8 M 55,8 M -
Capi. / Sales 2021 5,23x
Capi. / Sales 2022 3,49x
Nbr of Employees 34
Free-Float 88,4%
Chart JAGUAR HEALTH, INC.
Duration : Period :
Jaguar Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAGUAR HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,21 $
Average target price 5,88 $
Spread / Average Target 386%
EPS Revisions
Managers and Directors
Lisa A. Conte President, Chief Executive Officer & Director
Carol R. Lizak Chief Financial Officer
James J. Bochnowski Chairman
Pravin Ramsewak Chaturvedi Chief Scientific Officer
Jonathan S. Wolin Chief of Staff & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
JAGUAR HEALTH, INC.-46.42%56
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530